HONG KONG -- The year 2023 will be a tough one for pre-revenue biotechnology companies to go public in Hong Kong, according to Serena Shao, founder and managing partner of health care-focused investment firm Ascendum Capital.
DealStreetAsia
Hong Kong biotech IPOs face 'tough' 2023: Ascendum Capital founder
Serena Shao, also managing partner, says foreign investors backing out of market
"This year so far, there has been only one biotech IPO," in Hong Kong, says Serena Shao, founder of Ascendum Capital. "It's not performing very well, the market is still struggling." (Source photo by Getty Images and logo from Ascendum Capital's LinkedIn page)
Read Next
Latest on DealStreetAsia
